2024-2025 Key Trends and Updates: Securities Litigation Against Life Sciences Companies

In this webinar, we will discuss key updates and recent trends concerning securities class actions filed against publicly traded pharmaceutical, biotechnology, medical device and healthcare product and services companies (collectively, “life sciences companies”), which continue to be a primary target of the plaintiffs’ bar. After witnessing a drop in 2023, securities class action filings came roaring back in 2024, jumping above the number of cases filed in 2022 or 2023 and reaching 40% above the average since 1997. Life sciences companies remain by far the most targeted sector for federal stockholder class actions.

In addition to analyzing these overall trends, we will:

• examine data for class action filings in 2024 and trends based upon such data, focusing on filings against life sciences companies;
• review several significant, impactful recent decisions issued by federal courts particularly relevant to life sciences companies;
• provide in-depth analysis of the potential implications of these decisions, which involve challenges that life sciences companies often face; and
• discuss practical steps you can take to make informed choices related to your business, including your public disclosures.

This program is pending one hour CLE credit in California, New York, New Jersey, and/or Pennsylvania. 

The post 2024-2025 Key Trends and Updates: Securities Litigation Against Life Sciences Companies Webinar appeared first on Life Sciences Perspectives.